HEMOGENYX PHARM.PLC LS-01
Hemogenyx Pharmaceuticals Plc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood cancer. The company's lead product candidate is the HEMO-CAR-T therapy for the treatment and potential cure for relapsed and/or refractory acute myeloid leukemia. It also develops chimeric bait receptor to treat COVID-19 virus, a… Read more
HEMOGENYX PHARM.PLC LS-01 (5HU) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, HEMOGENYX PHARM.PLC LS-01 (5HU) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
HEMOGENYX PHARM.PLC LS-01 - Net Assets Trend (None–None)
This chart illustrates how HEMOGENYX PHARM.PLC LS-01's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for HEMOGENYX PHARM.PLC LS-01 (None–None)
The table below shows the annual net assets of HEMOGENYX PHARM.PLC LS-01 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to HEMOGENYX PHARM.PLC LS-01's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
HEMOGENYX PHARM.PLC LS-01 Competitors by Market Cap
The table below lists competitors of HEMOGENYX PHARM.PLC LS-01 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
CITIC SECURITIES-H-
MU:CI9
|
$26.60K |
|
Australis Capital Inc
PINK:AUSAF
|
$26.60K |
|
Hanil Iron & Steel Co. Ltd.
KQ:002220
|
$26.61K |
|
Mobi724 Global Solutions Inc
PINK:MOBIF
|
$26.61K |
|
CBRLAND PHARMA
BE:CBJ
|
$26.57K |
|
AdvancedAdvT Ltd
LSE:ADVT
|
$26.56K |
|
ALSEA (4FU.SG)
STU:4FU
|
$26.52K |
|
New Asia Holdings Inc
PINK:NAHD
|
$26.51K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in HEMOGENYX PHARM.PLC LS-01's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares HEMOGENYX PHARM.PLC LS-01's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently HEMOGENYX PHARM.PLC LS-01 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares HEMOGENYX PHARM.PLC LS-01's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| HEMOGENYX PHARM.PLC LS-01 (5HU) | €- | N/A | N/A | $26.58K |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |